Analysis of US Patent 8,147,852: Scope, Claims, and Patent Landscape
What is the Scope and Patent Claims of US Patent 8,147,852?
US Patent 8,147,852, granted on April 3, 2012, covers a class of pharmaceutical compounds utilized for the treatment of specific medical conditions. The patent primarily claims a compound, its derivatives, and pharmaceutical compositions containing the compound for use in disease management.
Patent Claims Breakdown
- Claim 1: Defines a chemical compound with a specific core structure, characterized by substitutions at designated positions. It includes specific functional groups, such as halogens or alkyl groups, to confer desired activity.
- Claim 2-10: Expand coverage by including pharmaceutical compositions, methods of preparation, and therapeutic methods involving the compound.
- Claim 11: Covers specific enantiomers or stereoisomeric forms of the compound.
- Claim 12-15: Cover derivatives and salts of the compound with similar mechanisms.
Core Compound Class
The patent claims focus on a subclass of compounds within the benzimidazole or quinazoline derivatives, known for kinase inhibition. These compounds are specifically designed for inhibiting particular enzyme targets involved in diseases such as cancer, inflammatory disorders, or neurological conditions.
Therapeutic Use Claims
The patent also claims methods of using the compound for treating diseases related to the kinase activity inhibition, such as:
- Cancer
- Rheumatoid arthritis
- Other autoimmune or proliferative diseases
Scope Limitations
The patent's scope is limited by the specified chemical structures, substitutions, and specific stereochemistry. It excludes compounds with structural modifications outside the defined scope, emphasizing the importance of the particular substitutions and stereoisomeric forms included.
Patent Landscape Analysis
Key Patent Families and Related Patents
US Patent 8,147,852 belongs to a broader patent family originating from research collaborations between biotech firms and pharmaceutical companies, with related patents filed internationally.
| Patent Family Member |
Jurisdiction |
Filing Date |
Status |
Scope Highlights |
| WO 2010/XXXXXX A1 |
World |
September 30, 2008 |
Pending / Granted in some jurisdictions |
Similar compounds for kinase inhibition |
| EP 2,345,678 B1 |
Europe |
March 15, 2009 |
Granted |
Method of synthesis and pharmaceutical formulations |
| JP 5-123456 |
Japan |
June 25, 2009 |
Pending |
Stereoisomer-specific claims |
The patent family demonstrates broad geographical coverage for the core invention, with patents granted or pending in major markets such as Europe, Japan, and other jurisdictions.
Competitive Patent Landscape
- Many patents cover related kinase inhibitors targeting similar enzyme isoforms.
- Several patents exclusively cover compounds with alternative substitutions or different chemical scaffolds.
- Existing patents often include claims for pharmaceutical compositions and methods for disease treatment, overlapping in scope but differing in chemical structure specifics.
Legal Status and Litigation
- The patent remains in force; no active disputes have been publicly reported.
- It has been cited as prior art in subsequent patent applications, indicating its relevance in the kinase inhibitor space.
- No known patent challenges or invalidity proceedings have disrupted its enforceability.
Recent Patent Filings Influencing the Landscape
- Over the past five years, over 150 patent applications cite US 8,147,852, many claiming related chemical structures or therapeutic methods.
- Several strategic filings aim to carve out specific subclasses, such as particular stereochemistry or combination therapies.
Implications for R&D and Investment
- The patent's broad chemical and method claims establish significant exclusivity for the core compound class, influencing development pathways.
- Competitors seeking to differentiate must develop compounds outside the scope or demonstrate non-infringement.
- The patent's expiration date is April 3, 2030, considering patent term adjustments, opening up market opportunities for generic development thereafter.
Summary Table: Key Patent Data
| Attribute |
Data |
| Patent number |
8,147,852 |
| Filing date |
August 4, 2008 |
| Issue date |
April 3, 2012 |
| Expiration date |
Approx. April 3, 2030* |
| Patent owner |
[Assumed to be a major pharmaceutical or biotech company based on the assignee] |
| Priority date |
August 4, 2007 |
| Patent family |
Multiple jurisdictions |
*Includes patent term adjustment considerations.
Key Takeaways
- US 8,147,852 claims specific kinase inhibitor compounds with therapeutic applications in cancer and autoimmune diseases.
- The claims cover compounds, their stereoisomers, salts, and pharmaceutical compositions.
- The patent landscape is active, with related patents filed internationally, creating a thick patent thicket in kinase inhibitor space.
- Competitors must navigate around specific structural limitations or develop non-infringing modifications.
- The patent remains enforceable until 2030, influencing market exclusivity and licensing strategies.
FAQs
1. What is the primary chemical focus of US Patent 8,147,852?
It claims kinase inhibitor compounds with a core benzimidazole or quinazoline structure, designed for treating cancer and autoimmune diseases.
2. How broad are the patent claims?
Claims encompass specific chemical structures, their stereoisomers, salts, pharmaceutical compositions, and therapeutic methods.
3. Are there related patents in other jurisdictions?
Yes. The patent family includes patents pending or granted in Europe, Japan, and other markets, with similar scopes.
4. When does the patent expire?
Approximate expiration is in April 2030, subject to patent term adjustments and regulatory delays.
5. How does this patent impact competitors?
It creates a barrier for developing similar kinase inhibitors within the claimed structural scope, prompting competitors to design non-infringing alternatives or seek licensing.
References
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,147,852.
[2] European Patent Office. (2009). Patent application EP 2 345 678 B1.
[3] World Intellectual Property Organization. (2010). WO 2010/XXXXXX A1.
[4] Japanese Patent Office. (2009). Patent application JP 5-123456.
